Cure8 research brief
Reactive TDM can help determine why a child with Crohn's disease is losing response to adalimumab and guide whether to escalate dose or switch biologics, which affects short-term management decisions.
pediatric gastroenterologists; clinicians treating children with Crohn's disease; parents/caregivers of pediatric patients on adalimumab; patients on biologic therapies
This single-center retrospective series enrolled 32 pediatric-onset Crohn's patients treated with adalimumab and compared those in clinical remission with those who experienced loss of response.
Reactive TDM (measuring trough levels and ADAs) was used after clinical loss of response to categorize mechanisms: some patients had therapeutic drug levels without ADAs and could remain on adalimumab; others had subtherapeutic levels or detectable ADAs prompting dose escalation or switching to another biologic.
The authors note that if these adjustments fail, evaluation for underlying monogenic disorders may be warranted. The paper is an abstract-level report of a real-world cohort rather than a randomized trial; findings describe how TDM informed clinical decisions at one center and are hypothesis-generating rather than definitive practice-changing evidence.
Single-center, retrospective study with a small sample size and partial abstract-level data. Results illustrate real-world use of reactive TDM but are not definitive evidence for changing standards of care.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
